Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/198666
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pignata, Sandro | - |
dc.contributor.author | Oza, Amit | - |
dc.contributor.author | Hall, Geoff | - |
dc.contributor.author | Pardo, Beatriz | - |
dc.contributor.author | Madry, Radoslaw | - |
dc.contributor.author | Cibula, David | - |
dc.contributor.author | Klat, Jaroslav | - |
dc.contributor.author | Montes Worboys, Ana | - |
dc.contributor.author | Glasspool, Rosalind | - |
dc.contributor.author | Colombo, Nicoletta | - |
dc.contributor.author | Pete, Imre | - |
dc.contributor.author | Herrero Ibáñez, Ana | - |
dc.contributor.author | Romeo Marín, Margarita | - |
dc.contributor.author | Ilieva, Rumyana | - |
dc.contributor.author | Timcheva, Constanta | - |
dc.contributor.author | Maio, Massimo di | - |
dc.contributor.author | Blakeley, Christopher | - |
dc.contributor.author | Taylor, Rosie | - |
dc.contributor.author | Barnicle, Alan | - |
dc.contributor.author | Clamp, Andrew | - |
dc.date.accessioned | 2023-05-30T08:31:34Z | - |
dc.date.available | 2023-05-30T08:31:34Z | - |
dc.date.issued | 2023-05-01 | - |
dc.identifier.issn | 0090-8258 | - |
dc.identifier.uri | http://hdl.handle.net/2445/198666 | - |
dc.description.abstract | Background. The open-label, single-arm, multicenter ORZORA trial (NCT02476968) evaluated the efficacy and safety of maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) who had tumor BRCA mutations (BRCAm) of germline (g) or somatic (s) origin or non-BRCA homologous recombination repair mutations (HRRm) and were in response to their most recent platinum-based chemotherapy after >= 2 lines of treatment. Methods. Patients received maintenance olaparib capsules (400 mg twice daily) until disease progression. Prospective central testing at screening determined tumor BRCAm status and subsequent testing determined gBRCAm or sBRCAm status. Patients with predefined non-BRCA HRRm were assigned to an exploratory cohort. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.ygyno.2023.03.019 | - |
dc.relation.ispartof | Gynecologic Oncology, 2023, vol. 172, p. 121-129 | - |
dc.relation.uri | https://doi.org/10.1016/j.ygyno.2023.03.019 | - |
dc.rights | cc by-nc-nd (c) Pignata, Sandro et al, 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer d'ovari | - |
dc.subject.classification | Genètica | - |
dc.subject.other | Ovarian cancer | - |
dc.subject.other | Genetics | - |
dc.title | Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-05-29T12:15:04Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37030280 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PIIS009082582300166X.pdf | 623.12 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License